- Category: Legal
- Organizations: Regeneron
Legal
Court sides with Regeneron in Eylea patent case against Novartis
Novartis claimed Regeneron’s Eylea (aflibercept) delivery system was in violation of its patent for Lucentis (ranibizumab), a competing AMD drug.
Legal
Regeneron settles with Sandoz over Eylea biosimilar patent infringement lawsuit
Agreement enables FDA-approved Enzeevu (aflibercept-abzv) to launch in Q4 2026, or potentially earlier.
Legal
Regeneron faces DOJ complaint in alleged Medicare overcharge of Eylea
The U.S. government alleges the company knowingly submitted false average sales prices and, as a result, inflated reimbursements rates.
Legal